Conflicting Roles of Molecules in Hepatocarcinogenesis: Paradigm or Paradox  by Feng, Gen-Sheng
Cancer Cell
MinireviewConflicting Roles of Molecules
in Hepatocarcinogenesis:
Paradigm or ParadoxGen-Sheng Feng1,2,*
1Department of Pathology, School of Medicine
2Molecular Biology Section, Division of Biological Sciences
University of California at San Diego, La Jolla, CA 92093-0864, USA
*Correspondence: gfeng@ucsd.edu
DOI 10.1016/j.ccr.2012.01.001
In delineating the molecular pathogenesis of hepatocellular carcinoma (HCC), recent experiments in mouse
tumor models have revealed unexpected tumor-suppressing effects in genes previously identified as pro-
oncogenic. This contradiction underscores the complexity of hepatocarcinogenesis and predicts uncertainty
in targeting these molecules for HCC therapy. Deciphering the underlying mechanisms for these paradoxical
functions will elucidate the complex molecular and cellular communications driving HCC development, and
will also suggest more thoughtful therapeutic strategies for this deadly disease.Hepatocellular carcinoma (HCC) is the third leading cause of
cancer-related death worldwide. However, the molecular and
cellular mechanisms underlying HCC initiation and development
are poorly understood. In recent studies, a number of groups
have employed cell type-specific gene knockout (KO) mouse
models to dissect HCC pathogenesis. This approach has no
doubt provided mechanistic insights into hepatocarcinogenesis.
However, opposing roles in promoting and suppressing HCC
have been reported for the same molecules in different animal
models (Figure 1). These conflicting results do not necessarily
obscure the understanding of molecular pathogenesis in HCC.
Instead, further experiments carefully designed to decipher the
opposing roles will lead to better understanding of HCCdevelop-
ment.
Contradictory Results from Different Animal Models
The NF-kB pathway that promotes cell survival and proliferation
is constitutively activated in a variety of tumors. Consistently,
several groups have reported tumor-promoting effects of NF-
kB in mouse models (Haybaeck et al., 2009; Pikarsky et al.,
2004). Removal of Mdr-2 P-glycoprotein triggered spontaneous
development of cholestatic hepatitis and consequently HCC in
mice, and inactivation of the NF-kBpathway in hepatocytes sup-
pressed HCC progression initiated by Mdr-2 deletion (Pikarsky
et al., 2004). By controlling the timing of shutting down the NF-
kB pathway, the authors demonstrated that NF-kB was required
for the later stage of HCC progression, without significant impact
on transformation or the early stage of tumor development. In
contrast, Karin’s group reported that hepatocyte-specific abla-
tion of Ikkb (IkkbDhep), a kinase required for the activation of
NF-kB, resulted in dramatic increase in HCC development
induced by the chemical carcinogen diethylnitrosamine (DEN),
pointing to an antitumor effect of NF-kB in the liver (Maeda
et al., 2005). DEN, as a procarcinogen, can bemetabolically acti-
vated in hepatocytes and forms bulky DNA adducts that induce
genomic instability and gene mutations (Aleksic et al., 2011;
Verna et al., 1996). The carcinogenic effect of DEN can be150 Cancer Cell 21, February 14, 2012 ª2012 Elsevier Inc.enhanced by other tumor promoters, such as phenobarbital,
in adult mice. Consistent with the increased susceptibility of
IkkbDhep mice to DEN-induced tumorigenesis, hepatocyte-
specific deletion of NEMO/Ikkg, another component of the Ikk
complex, leads to spontaneous development of HCC, following
hepatic steatosis and chronic inflammation in mice (Luedde
et al., 2007).
Highlighting a similar paradox, several groups have demon-
strated either tumor-promoting or tumor-suppressing actions
of Jnk kinases in HCC. Hui et al. detected high levels of p-Jnk1
in human HCC lesions and found that the incidence of DEN/
phenobarbital-induced HCC was significantly reduced in
Jnk1/ but not in Jnk2/ mice (Hui et al., 2008). Consistently,
siRNA-mediated Jnk1 or Jnk1 together with Jnk2 knockdown
in Huh7 human HCC cells suppressed in vitro proliferation and
tumor formation as subcutaneous xenografts in nude mice,
with no effect observed for Jnk2 knockdown. In contrast, Davis
and colleagues presented data suggesting a tumor-suppressing
effect of Jnk1 and Jnk2 in hepatocytes (Das et al., 2011). The
authors generated mutant mice (HDJnk) with Jnk1 and Jnk2 defi-
ciency in hepatocytes by deleting Jnk1 specifically in hepato-
cytes in the Jnk2/ background. Their results indicate that
combined deficiency of Jnk1 and Jnk2 leads to increased tumor
sizes in DEN-treated mice.
Stat3 clearly has a pro-oncogenic function, based on the
detection of activating mutations or enhanced p-Stat3 signals
in different types of cancer (Calvisi, 2011; Yu et al., 2009).
However, both pro- and anti-oncogenic activities of Stat3
in HCC development were observed in hepatocyte-specific
Stat3 knockouts, transgenic mice expressing dominant-active
or -negative mutants of Stat3, or tumor-bearing animals treated
with Stat3 inhibitors (Lin et al., 2009; Schneller et al., 2011; Wang
et al., 2011b). Interestingly, hepatocyte-specific deletion of
the tyrosine phosphatase Shp2 resulted in a marked increase
in DEN-induced HCC incidence, which was compromised
by the additional removal of Stat3 (Bard-Chapeau et al.,
2011). However, deleting Stat3 alone also led to enhanced
Figure 1. A Simplified Model for the Pro- and Anti-Oncogenic
Activities of the Same Molecules in Hepatocarcinogenesis
(A) MET, NF-kB, Stat3, Jnk, Shp2, and b-catenin constitute pathways that
normally promote cell survival and proliferation. Aberrant activation or
overexpression of these molecules enhances cell transformation and tumori-
genesis.
(B) Removal or inactivation of these protumorigenic molecules, which normally
causes hepatocyte damage and death, also enhances HCC development
under certain conditions.
(C) One possible explanation is that loss of a prosurvival signal enhances
chronic hepatic damage, increases production of inflammatory cytokines,
and triggers excessive compensatory proliferation of hepatocytes and/or
progenitor cells, resulting in elevated hepatocarcinogenesis.
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CCl4 (Wang et al., 2011b) as compared to wild-type mice.
Contrasting roles in HCC have also been observed for b-cate-
nin, a chief effector in the Wnt pathway. Consistent with
the detection of activating mutations in the b-catenin gene
(CTNNB1) in HCCs (de La Coste et al., 1998), Monga and
colleagues reported that overexpression of a dominant-active
b-catenin mutant in hepatocytes accelerated DEN-induced
hepatocarcinogenesis (Nejak-Bowen et al., 2010). Surprisingly,
the same group found that hepatocyte-specific Ctnnb1 KO
mice also displayed higher susceptibility to DEN-induced tumor-
igenesis, due to excessive oxidative stress, hepatic injury, and
inflammation (Zhang et al., 2010). Therefore, HCC is promoted
by both gain and loss of b-catenin function in hepatocytes
(Nejak-Bowen and Monga, 2011).
The opposing roles in promoting and suppressing HCC are not
restricted to intracellular signaling molecules. The HGF receptor
(MET) tyrosine kinase system represents a classic pro-onco-
genic signaling pathway, and dominant-active mutations of
MET have been found in human HCC and other tumors (Birch-
meier et al., 2003). As expected, overexpression of MET in hepa-tocytes promoted HCC development in transgenic mice (Wang
et al., 2001). Turning off the transgene expression in tumor-
bearing mice led to increased cell apoptosis and impaired prolif-
eration resulting in tumor regression, suggesting that MET is
required in genesis and maintenance of HCC. Surprisingly,
Thorgeirsson’s group showed that hepatocyte-specific Met KO
mice exhibited higher susceptibility to DEN-induced tumorigen-
esis and developed larger and more tumors than control animals
(Takami et al., 2007).
Possible Explanations and Unanswered Questions
How should one interpret these conflicting findings? One can
easily explain the tumor-promoting effect of these molecules
based on their known pro-proliferation and anti-apoptosis func-
tions. It is certainly more challenging to understand the unantic-
ipated antitumor effect of these molecules. In dissecting the
underlying mechanisms, several groups have shown that the
outcomedepends on the cell types in the liver fromwhich a target
gene is removed (Das et al., 2011; Maeda et al., 2005). Deleting
Ikkb or Jnk1 and Jnk2 in hepatocytes only by Alb-Cre enhanced
DEN-induced HCC, whereas inactivating the same gene in both
hepatocytes and nonparenchymal cells using Mx1-Cre sup-
pressed tumorigenesis. Based on these and other experimental
data, one emerging theory is that the loss of a prosurvival
molecule triggers chronic hepatic injury, which in turn enhances
compensatory proliferation through elevated production of
cytokines from infiltrated inflammatory cells, including Kupffer
cells. Excessive and continuous proliferation of hepatocytes
or progenitor cells eventually leads to spontaneous or DEN-
induced neoplastic growth in the liver (Figure 1).
In the multistage pathogenic process, elevated hepatocyte
death is the first step in promoting hepatocarcinogenesis.
Indeed, deletion of Ikkb or b-catenin in hepatocytes caused
dramatically increased accumulation of reactive oxygen species,
and feeding the mice with antioxidants reduced HCC incidence
(Maeda et al., 2005; Zhang et al., 2010). Additional deletion of
FADD, an essential adaptor molecule downstream of death
receptors, alleviated excessive apoptosis, inflammation, and
steatohepatitis in NemoLPC-KOmice (Luedde et al., 2007), result-
ing in decreased tumorigenesis in Fadd and Nemo compound
mutant mice (M. Pasparakis, personal communication).
Enhanced cell death may increase compensatory proliferation
of tumor-initiating cells (TICs) originating from mature hepato-
cytes or progenitor cells, and several lines of evidence support
this notion. For example, proliferating cells were frequently
located around apoptotic cells in centrilobular lesions after
DEN exposure (Maeda et al., 2005). Additional deletion of Jnk1
in IkkbDhep mice suppressed compensatory proliferation
following DEN injection and consequently reduced tumor burden
(Sakurai et al., 2006). Severe steatosis induced by loss of PTEN
enhanced hepatocyte death and compensatory proliferation of
TICs (Galicia et al., 2010). Although loss of either Shp2 or Stat3
in hepatocytes led to increased tumorigenesis, combined dele-
tion of both did not show an additive or synergistic effect but
interestingly a neutralizing result (Bard-Chapeau et al., 2011),
which is likely due to impaired compensatory proliferation in
the absence of both Shp2 and Stat3 (our unpublished data). A
similar compromising effect of Tak1 and NEMO ablation was
observed (Bettermann et al., 2010), although it was unclearCancer Cell 21, February 14, 2012 ª2012 Elsevier Inc. 151
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proliferation potential.
Pro-inflammatory cytokines play important roles in these HCC
animal models. Hepatic expression of TNFa, IL-6, and HGF was
increased in IkkbDhep mice (Maeda et al., 2005). Higher circu-
lating levels of IL-1a and IL-6 were detected in IkkbDhep and
p38aDhep mice following DEN injection, which were alleviated
by antioxidant treatment that prevented hepatocyte death
(Sakurai et al., 2008). Blocking IL-1a action by injection of IL-
1R antagonist or ablation of IL-1R suppressed DEN-induced
IL-6 production, compensatory proliferation, and tumorigenesis.
These results suggest that IL-1a released from dying hepato-
cytes stimulates production of IL-6, which in turn induces
surviving hepatocytes to proliferate (Sakurai et al., 2008).
A similar mechanism involving paracrine action of cytokines
was identified inmicewith Jnk or Stat3 deficiency in hepatocytes
only or in hepatocytes plus nonparenchymal cells (Das
et al., 2011; Horiguchi et al., 2008). In aggregate, these results
highlight the importance of hepatic cell communication in liver
tumorigenesis.
It remains to be elucidated at which stage(s) the paracrine
cytokines and the infiltrated inflammatory cells contribute to
hepatocarcinogenesis. The ability to isolate TICs at early stages
of HCC development following DEN exposure (He et al., 2010)
will help clarify this issue. Opposite effects on tumorigenesis
were observed when deleting the same gene using Alb-Cre
and Mx1-Cre lines, respectively (Das et al., 2011; Maeda et al.,
2005). It will be interesting to isolate and compare TICs from
the two mutant mouse lines. If mutant TICs of the two origins
display opposite growth properties in vitro and in allografts in
recipient animals, the result would suggest that the initial trans-
formation event is already influenced by the hepatic microenvi-
ronment. However, if the TICs of the two origins display similar
phenotypes, one may conclude that the inflammatory cytokines
or the hepatic microenvironment influences tumor progression
without effect on TIC genesis.
One issue that could affect the interpretation of data from
hepatocyte-specific KO mice is the timing and efficiency of
Cre expression. The nature of the few surviving hepatocytes
that become TICs and eventually develop into HCCs remains
to be determined. It is possible that a few hepatocytes have
escaped Cre-mediated DNA excision and thus gain survival
and proliferative advantages over neighboring cells with a pro-
survival gene ablated. Arguing against this theory are the data
that the targeted genes were efficiently deleted in tumors
(Bard-Chapeau et al., 2011; Das et al., 2011; Maeda et al.,
2005; Sakurai et al., 2008). However, the possibility that a target
gene was intact in TICs but was deleted later during cancer
progression, which no longer requires the gene product, has
not been excluded. Indeed, one report on HCC induced
by Ddb1 deletion suggests that HCC originates from hepato-
cytes that escaped Alb-Cre-mediated gene ablation (Yamaji
et al., 2010). In another study, Chen and colleagues found that
liver tumors developed from b-catenin-positive hepatic progen-
itor cells in Alb-Cre-mediated Ctnnb1 deletion (Wang et al.,
2011a). To unequivocally determine the gene deletion status
during HCC initiation and progression, it is important to use
inducible and tightly controlled Cre expression strategies that
are yet to be optimized.152 Cancer Cell 21, February 14, 2012 ª2012 Elsevier Inc.Thus far, most studies have largely focused on the final
outcome of HCC development after a long period of DEN treat-
ment. More rigorous analyses of the kinetics of hepatic injury and
disorders associated with early stages of tumorigenesis will
provide mechanistic insights into the pathogenic process. With
regard to the hepatic microenvironment in tumorigenesis, rela-
tive contributions of Kupffer cells versus other infiltrating cell
types will need to be clarified. Possible roles of oval cells and
hepatic stellate cells in HCC development need to be carefully
examined, which may help interpret the seemingly contradictory
findings.
There are many open questions for the antitumor effect of pro-
tumorigenic molecules. The cell death-compensatory prolifera-
tion-transformation-hepatocarcinogenesis scheme (Figure 1) is
likely an oversimplified model, and other mechanisms may also
be involved in promoting HCC development. Inactivation of
one protumorigenic pathway in hepatocytes may lead to aber-
rant activation of another. For example, overexpression of
PDGFRa and c-Myc was detected in b-catenin-deficient livers
(Zhang et al., 2010), and upregulated Stat3 activity was observed
in the liver of IkkbDhep or Shp2Dhep mice (Bard-Chapeau et al.,
2011; He et al., 2010). Rather than showing increased apoptosis,
Ikkb-deficient TICs were found to exhibit higher survival and
proliferative capacity in vitro, although the molecular basis is
not fully understood (He et al., 2010). Thus, excessive compen-
satory reaction to loss of a proliferative signal may also
contribute to the unexpected tumor-promoting effect observed
upon removal of a protumorigenic molecule, at least in some
cases.
Implications in Human HCC Pathogenesis and Therapy
As described above, either aberrant gain or loss of function of the
same molecule can lead to malignant growth, reinforcing the
concept that homeostasis is critical for preventing tumorigenesis
in the liver. A critical question is whether the results from these
animal experiments are relevant to human HCCs. Constitutive
activation of MET, b-catenin, NF-kB, and Stat3 has been
detected in human HCC samples or cell lines (Birchmeier et al.,
2003; Calvisi, 2011; He et al., 2010; Nejak-Bowen and Monga,
2011; Yu et al., 2009). In contrast, there has been almost no
definitive report of loss-of-function mutations in these genes in
humanHCCs, thus the paucity of evidence to support their tumor
suppressor role. Although deficient expression of Shp2 was
detected in primary human HCCs (Bard-Chapeau et al., 2011),
it was unclear whether Shp2 deficiency plays a causative role
in their pathogenesis. Genome-wide sequencing of human
HCC samples worldwide may identify inactivating mutations in
these proto-oncogenes, most likely at low frequencies.
Despite the rare detection of corresponding mutations in
humans, these mouse mutants recapitulate many aspects of
pathological features in human patients, including chronic hepa-
tocyte damage, elevated oxidative stress, inflammation, fibrosis,
steatohepatitis, and cholestasis. Therefore, these animal models
are useful for understanding the molecular and cellular mecha-
nisms of liver cancer in humans. In particular, the mouse models
provide access to early events in tumorigenesis, particularly the
dynamic interplay of TICs with the hepatic microenvironment.
Given the 100% penetrance in DEN-induced carcinogenesis
and the high degree of similarity in pathogenesis, mutant mice
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diagnosis of HCC, the significance of which cannot be over-
stated given the current poor prognosis of patients with late
stages of HCC.
Personalized therapeutic strategies can be developed based
on dominantly activating mutations detected in tumors. A potent
MET inhibitor might be effective in treating a liver cancer patient
with an activating MET mutation (You et al., 2011). However, the
pro- and anti-oncogenic roles of signaling molecules and the cell
type-specific effects of gene deletion described above bring
uncertainty to using inhibitors of these molecules as anticancer
drugs, as reported for Stat3 inhibitors (Yue and Turkson, 2009).
One interesting idea is the development of anti-HCC therapeu-
tics by sorting beneficial from harmful functions of a signaling
molecule such as b-catenin (Nejak-Bowen and Monga, 2011).
Due to the compensatory upregulation of one pathway in reac-
tion to the loss of another, simultaneous blockade of several
pathways by a cocktail of inhibitors may be a more effective
approach. Additional removal of Stat3 reversed the tumor-
promoting effect of Shp2 deletion (Bard-Chapeau et al., 2011),
and inhibition of PDGFRa suppressed tumorigenesis induced
by ablation of b-catenin (Zhang et al., 2010).
The debate over the relevance of mouse data to human HCCs
will likely continue. However, in-depth molecular analyses in
animal models cannot be replaced by examination of human
HCC specimens. The opposing roles of signaling molecules
revealed by these mouse models indicate a need for reassess-
ment of current approaches in drug targeting and screening.
Finally, although the discussion in this article focuses on HCC,
contrasting roles of NF-kB have been observed in other types
of cancer, such as skin cancer (van Hogerlinden et al., 2002).
Therefore, it is crucial to elucidate factors that regulate various
functions of each of these oncogenic pathways.ACKNOWLEDGMENTS
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